Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Per a pediatric-endocrinology clinical study (Lawrence 2004), raloxifene achieved an 86% rate of >50% breast-tissue reduction for gynecomastia vs only 41% with tamoxifen. Acts as an estrogen antagonist in breast tissue while protecting bone. NOT recommended for PCT - at double the standard dose (120mg/day) it only modestly raises testosterone (total T +20%, free T +16% over 3 months in healthy older men), far weaker HPTA stimulation than tamoxifen. FDA-approved for osteoporosis and breast cancer risk reduction. Rated 1 (basically natty) - its real-world use is as a breast-tissue anti-estrogen for gyno treatment/prevention, which does not move the muscular/physique ceiling, and the testosterone bump it produces is weak, seen only at double dose in men with an already-normal (non-suppressed) axis, and not clinically meaningful enough to count as genuine anabolic hormone stimulation.
Overview
A second-generation SERM (benzothiophene class) that is clinically superior to tamoxifen specifically for treating and reversing gynecomastia. Studies show 86% of patients achieve >50% breast tissue reduction vs only 41% with tamoxifen. Acts as an estrogen antagonist in breast tissue while being an agonist in bone. NOT recommended for PCT due to weak testosterone stimulation.
Important Warnings
- •NOT recommended for PCT - weak testosterone stimulation
- •Contraindicated with history of venous thromboembolism (DVT, PE)
- •Discontinue 3 days before surgery or prolonged immobility
- •BLACK BOX WARNING: Increased stroke risk in women with coronary heart disease
- •Most effective for recent-onset gyno - less effective for long-standing fibrotic tissue
- •Not FDA-approved for gynecomastia - all use is off-label
- •Very low bioavailability (~2%) due to extensive first-pass metabolism
Purpose & Use Cases
Gynecomastia Treatment
The primary and best use. The main clinical evidence comes from pediatric-endocrinology studies of pubertal gynecomastia (ages 12-16.6), where 86-93% of patients achieved >50% breast tissue reduction, significantly better than tamoxifen (41%). Adult/on-cycle use extrapolates the FDA-approved 60mg adult dose off-label; it is not separately validated in adult steroid-induced gyno.
Gynecomastia Prevention
Can be used on-cycle at 30-60mg daily to prevent gyno development during aromatizing steroid cycles.
Breast Pain Resolution
Studies show 100% pain resolution in gynecomastia patients.
Bone Protection
Acts as an estrogen agonist in bone, increasing bone mineral density.
Benefits
- Superior to tamoxifen for gynecomastia (86% vs 41% achieve >50% reduction)
- 100% pain resolution in studies
- 0% recurrence rate at 3-year follow-up
- No side effects reported in gynecomastia studies
- More selective breast tissue antagonism than tamoxifen
- No uterine stimulation (unlike tamoxifen)
- Bone-protective estrogenic effects
- Pure ERbeta antagonist - may provide more complete breast tissue blockade
Good to Know
The best SERM for gyno - but not for PCT
Raloxifene and tamoxifen are both SERMs, but their tissue selectivity differs. Raloxifene is the stronger breast-tissue antagonist (a pediatric-endocrinology study found ~86% achieve >50% breast-tissue reduction vs ~41% with tamoxifen), making it the go-to for treating existing gynecomastia. But its HPTA/testosterone stimulation is comparatively modest even at double the normal dose (120mg/day raised free testosterone only ~16% over 3 months in one study of older men) and far weaker than tamoxifen's, so it is a poor axis-restart drug. The rule of thumb: raloxifene for gyno, tamoxifen or clomiphene for PCT.
Why "which SERM" depends on the target tissue
SERMs act differently in different tissues. Tamoxifen is a partial agonist in the uterus and a strong hypothalamic antagonist (good for restarting testosterone); raloxifene is a purer breast/ERbeta antagonist with no uterine stimulation and weaker hypothalamic action. That is the whole reason to pick one over the other - it is not about potency, it is about where you want the estrogen receptor blocked.
Works best on recent, glandular gyno
SERMs shrink active, estrogen-driven glandular tissue - so raloxifene is most effective on recent-onset gyno (the "puffy nipple" or tender-lump stage). Once the lump has matured into fibrotic scar tissue (months to years old), no SERM will dissolve it and surgery becomes the only reliable fix. Acting early is the single biggest determinant of success.
Blood clots are the real risk
Like tamoxifen, raloxifene raises the risk of venous thromboembolism (DVT/PE), roughly 1 in 100 in the osteoporosis population, highest in the first few months. Do not use it with a personal history of clots, and stop it before surgery or prolonged immobility (e.g. long flights). Leg swelling/pain or chest pain/shortness of breath warrants immediate medical attention.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 30 – 60 mg/day |
| Intermediate | 60 – 60 mg/day |
| Advanced | 60 – 60 mg/day |
Standard gyno protocol: 60mg daily for 3-9 months, the dose and duration used in the pivotal pediatric-endocrinology study (Lawrence 2004, 12-16.6 year old subjects) that reported 86% response. Community reports describe a more aggressive taper (higher dose short-term, then 30mg maintenance) though this specific protocol is not clinically documented. On-cycle prevention: 30-60mg daily (community-derived, not clinically studied for this indication). Per clinical prescribing guidance for raloxifene generally, supplement with Vitamin D (400-800 IU) and Calcium (1,000-1,500mg) daily if diet is insufficient. Most effective for recent-onset gyno - less effective for long-standing fibrotic tissue.
Side Effects
Hot Flashes
commonMost common side effect: 9.7% of Evista users vs 6.4% on placebo in the pivotal osteoporosis trials. Usually occurs in the first 6 months.
Usually tolerable and may decrease with time.
Leg Cramps/Muscle Spasms
commonReported in 7.0% of users vs 3.7% on placebo in the pivotal osteoporosis trials.
Ensure adequate magnesium and potassium intake. Stretching may help.
Peripheral Edema
commonSwelling in extremities, reported in 5.2% of users vs 4.4% on placebo in the pivotal osteoporosis trials.
Usually mild. Elevate legs if bothersome.
Venous Thromboembolism (VTE)
rareIncludes DVT and pulmonary embolism. Occurs in approximately 1 in 100 patients. Highest risk in first 4 months. This is the most serious risk.
Contraindicated if history of VTE. Discontinue 3 days before surgery or prolonged immobility. Seek immediate medical attention for leg pain/swelling or chest pain/shortness of breath.
Joint Pain (Arthralgia)
uncommonSome users report joint discomfort.
Usually manageable.
General Mitigation Strategies
In the clinical gynecomastia study (Lawrence 2004), NO side effects were reported in any patients receiving raloxifene for 3-9 months. VTE risk is the primary serious concern - do not use if you have a history of blood clots. Discontinue before surgery or long travel. Overall very well-tolerated for gynecomastia treatment.
Support Supplements
Ancillary supplements commonly run alongside Raloxifene to manage side effects, support the target tissue, or fill nutrient demands it creates.
Vitamin D + Calcium
Standard clinical guidance alongside raloxifene (from its osteoporosis indication) is to ensure adequate vitamin D and calcium intake, since inadequate levels can blunt its bone-protective agonist effect.
- Dose
- Vitamin D 400-800 IU/day; Calcium 1,000-1,500mg/day (diet + supplement combined)
- Timing
- Daily, with food
- When
- Most relevant for longer (3-9 month) courses; less critical for short on-cycle prevention use.
Post Cycle Therapy (PCT)
Raloxifene is NOT recommended as a standalone PCT drug. In a 3-month placebo-controlled study of healthy men aged 60-70 (Duschek 2004), 120mg/day (double the standard 60mg dose) raised LH ~29%, FSH ~21%, total testosterone ~20% and free testosterone ~16%, with only a modest ~7% rise in SHBG - a real but comparatively weak HPTA stimulus next to tamoxifen. That study was also done in older men with a normal, non-suppressed axis rather than post-cycle bodybuilders recovering from AAS-induced suppression, so its relevance to actual PCT recovery is unproven. Nolvadex and Clomid remain the standard, better-studied choices for PCT. Raloxifene's primary use is gynecomastia treatment/prevention, not PCT.
How It Works
Raloxifene binds to estrogen receptors with affinity similar to estradiol (Kd ~50 pM). It acts as a partial agonist of ERalpha and a pure antagonist of ERbeta. In breast tissue, it blocks estrogen receptors, preventing estrogen-mediated cell proliferation. In bone, it acts as an agonist, increasing bone mineral density. Unlike tamoxifen, it has no estrogenic activity in the uterus. Also acts as an agonist of GPER (G protein-coupled estrogen receptor).
Hormonal & Androgenic Profile
Raloxifene IS a SERM/anti-estrogen itself - it does not need an AI. Unlike an aromatase inhibitor, it does not lower systemic estradiol; it blocks the estrogen receptor in breast tissue (treating/preventing gyno) while acting as an estrogen agonist in bone. Some users stack it with an AI for stubborn on-cycle gyno, but raloxifene alone is the typical first-line choice for treating existing gyno.
In postmenopausal women (the studied population), raloxifene lowers LDL cholesterol and fibrinogen while raising HDL2, but raises venous thromboembolism risk roughly 2-3x (about 1 in 100 patients, highest in the first 4 months) and carries a black-box warning for increased stroke mortality in women with existing coronary heart disease. Long-term cardiovascular safety data in men are not established.
Fundamentals
Reference on the practices relevant to Raloxifene: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- Raloxifene for on-cycle gyno prevention/treatment
- Raloxifene + AI for stubborn gyno cases
- Use Nolvadex (not Raloxifene) for PCT
Legal Status
FDA-approved for osteoporosis and breast cancer risk reduction. Not approved for gynecomastia (off-label use).
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Raloxifene is explicitly prohibited as an anti-estrogenic substance (SERM) under S4.2.
References
- PubMed - Raloxifene vs Tamoxifen for Pubertal Gynecomastia (Lawrence 2004)
- PMC - Gynecomastia Pharmacological Treatments Systematic Review
- PubMed - Raloxifene Effects on Gonadotrophins, Testosterone and Lipids in Healthy Elderly Men (Duschek 2004)
- StatPearls - Raloxifene
- DrugBank - Raloxifene
- DailyMed - EVISTA (Raloxifene) FDA Label